Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

4
ESMO-MCBS v1.1
Scorecard version: 1

Indication details

Tumour Type
Thoracic Malignancies
Tumour Sub-type
Non-small-cell Lung Cancer
Tumour Sub-Group
ALK+
Tumour stage
Metastatic
Control Arm
Chemotherapy (pemetrexed or docetaxel)
Treatment Setting
Previously treated with chemotherapy and crizotinib ALK-positive stage IIIB or IV
Trial Name
ASCEND-5

Primary Outcome(s)

Primary Outcome(s)
PFS
Form(s)
Form 2b

Outcome Data

PFS Control
1.6 months
PFS Gain
3.8 months
PFS HR
0.49 (0.36-0.67)
QoL Comment
Improved overall health-related QoL
Toxicity Comment
Similar toxicity

Final Score (after adjustments)

Preliminary non-curative score
3
QoL adjustment
1+
Final non-curative Score
4
Release date
15.05.2019

DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; HR, hazard ratio; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings